World Pharma News Digest - 23.04.2012
2 views
Skip to first unread message
Ruslan David
Apr 23, 2012, 5:04:50 AM4/23/12
to worldph...@googlegroups.com
Novartis updates US label on Gilenya® following discussions with the FDA
Novartis announced agreement with the US Food and Drug Administration (FDA) on label changes for Gilenya® (fingolimod). The update to the Gilenya prescribing information includes patient selection parameters to aid in the identification of candidates for Gilenya treatment and more specific recommendations for treatment initiation for patients with relapsing forms of MS in the United States.
Read more...
http://www.worldpharmanews.com/novartis/2051-novartis-updates-us-label-on-gilenyar-following-discussions-with-the-fda
Novartis announced agreement with the US Food and Drug Administration (FDA) on label changes for Gilenya® (fingolimod). The update to the Gilenya prescribing information includes patient selection parameters to aid in the identification of candidates for Gilenya treatment and more specific recommendations for treatment initiation for patients with relapsing forms of MS in the United States.
Read more...
http://www.worldpharmanews.com/novartis/2051-novartis-updates-us-label-on-gilenyar-following-discussions-with-the-fda
Key protein responsible for controlling nerve cell protection
A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate the transfer of information between nerve cells in the brain. The discovery, made by neuroscientists at the University of Bristol and published in Nature Neuroscience and PNAS, could lead to novel new therapies for stroke and epilepsy.
Read more...
http://www.worldpharmanews.com/research/2050-key-protein-responsible-for-controlling-nerve-cell-protection
A key protein, which may be activated to protect nerve cells from damage during heart failure or epileptic seizure, has been found to regulate the transfer of information between nerve cells in the brain. The discovery, made by neuroscientists at the University of Bristol and published in Nature Neuroscience and PNAS, could lead to novel new therapies for stroke and epilepsy.
Read more...
http://www.worldpharmanews.com/research/2050-key-protein-responsible-for-controlling-nerve-cell-protection
Women don't receive the same treatment as men for heart disease the world-over
Women with acute coronary syndrome (ACS) receive inferior or less aggressive treatment compared to men, according to three large studies presented today at the World Congress of Cardiology.
Read more...
http://www.worldpharmanews.com/research/2049-women-dont-receive-the-same-treatment-as-men-for-heart-disease-the-world-over
Women with acute coronary syndrome (ACS) receive inferior or less aggressive treatment compared to men, according to three large studies presented today at the World Congress of Cardiology.
Read more...
http://www.worldpharmanews.com/research/2049-women-dont-receive-the-same-treatment-as-men-for-heart-disease-the-world-over
GSK confirms offer to acquire Human Genome Sciences for US$13.00 per share in cash
GlaxoSmithKline plc (LSE: GSK) confirms that it made an offer to the Board of Directors of Human Genome Sciences (HGS, NASDAQ: HGSI) on 11th April proposing to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
Read more...
http://www.worldpharmanews.com/gsk/2048-gsk-confirms-offer-to-acquire-human-genome-sciences-for-us1300-per-share-in-cash
GlaxoSmithKline plc (LSE: GSK) confirms that it made an offer to the Board of Directors of Human Genome Sciences (HGS, NASDAQ: HGSI) on 11th April proposing to acquire all of the outstanding shares of HGS for US$13.00 per share in cash.
Read more...
http://www.worldpharmanews.com/gsk/2048-gsk-confirms-offer-to-acquire-human-genome-sciences-for-us1300-per-share-in-cash
GSK provides update on corporate responsibility commitments in 2011 report
GlaxoSmithKline (GSK) has published its Corporate Responsibility Report, in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Read more...
http://www.worldpharmanews.com/gsk/2047-gsk-provides-update-on-corporate-responsibility-commitments-in-2011-report
GlaxoSmithKline (GSK) has published its Corporate Responsibility Report, in which the company reiterates its commitment to operate responsibly, openly and transparently and sets out advances made on this agenda during 2011.
Read more...
http://www.worldpharmanews.com/gsk/2047-gsk-provides-update-on-corporate-responsibility-commitments-in-2011-report
Advances in personalized medicine for lung cancer
Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.
Read more...
http://www.worldpharmanews.com/research/2046-advances-in-personalized-medicine-for-lung-cancer
Several new studies that may help doctors tailor lung cancer treatment to the characteristics of individual patients and of their tumors are being presented at the 3rd European Lung Cancer Conference in Geneva.
Read more...
http://www.worldpharmanews.com/research/2046-advances-in-personalized-medicine-for-lung-cancer
Abbott's investigational treatment for advanced Parkinson's disease demonstrates positive results
Abbott (NYSE: ABT) announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).
Read more...
http://www.worldpharmanews.com/abbott/2045-abbotts-investigational-treatment-for-advanced-parkinsons-disease-demonstrates-positive-results
Abbott (NYSE: ABT) announced the results from a Phase 3 trial evaluating the company's investigational compound for advanced Parkinson's disease, levodopa-carbidopa intestinal gel (LCIG).
Read more...
http://www.worldpharmanews.com/abbott/2045-abbotts-investigational-treatment-for-advanced-parkinsons-disease-demonstrates-positive-results
Canadian study suggests off-label prescribing of medications is common
A study evaluating off-label prescribing of medications in a primary care network in Canada suggests the practice is common, although it varies by medication, patient and physician characteristics, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
Read more...
http://www.worldpharmanews.com/research/2044-canadian-study-suggests-off-label-prescribing-of-medications-is-common
A study evaluating off-label prescribing of medications in a primary care network in Canada suggests the practice is common, although it varies by medication, patient and physician characteristics, according to a report published Online First by Archives of Internal Medicine, a JAMA Network publication.
Read more...
http://www.worldpharmanews.com/research/2044-canadian-study-suggests-off-label-prescribing-of-medications-is-common
PharmaNews.eu / Latest News
FORXIGA (dapagliflozin) receives positive CHMP opinion
http://www.pharmanews.eu/astrazeneca/1040-forxiga-dapagliflozin-receives-positive-chmp-opinion
http://www.pharmanews.eu/astrazeneca/1040-forxiga-dapagliflozin-receives-positive-chmp-opinion
Advances in personalized medicine for lung cancer
http://www.pharmanews.eu/research-and-development/1039-advances-in-personalized-medicine-for-lung-cancer
http://www.pharmanews.eu/research-and-development/1039-advances-in-personalized-medicine-for-lung-cancer
International industry gathering assumes leading position
http://www.pharmanews.eu/conferences-and-events/1038-international-industry-gathering-assumes-leading-position
http://www.pharmanews.eu/conferences-and-events/1038-international-industry-gathering-assumes-leading-position
Hypertension study proves treatment with RAAS inhibitors saves lives
http://www.pharmanews.eu/research-and-development/1037-hypertension-study-proves-treatment-with-raas-inhibitors-saves-lives
http://www.pharmanews.eu/research-and-development/1037-hypertension-study-proves-treatment-with-raas-inhibitors-saves-lives
Towards a robust global framework for conduct and oversight of clinical trials
http://www.pharmanews.eu/ema/1036-towards-a-robust-global-framework-for-conduct-and-oversight-of-clinical-trials
http://www.pharmanews.eu/ema/1036-towards-a-robust-global-framework-for-conduct-and-oversight-of-clinical-trials
European regulators propose way forward for publication of full clinical trial data
http://www.pharmanews.eu/ema/1035-european-regulators-propose-way-forward-for-publication-of-full-clinical-trial-data
http://www.pharmanews.eu/ema/1035-european-regulators-propose-way-forward-for-publication-of-full-clinical-trial-data
Abbott's HUMIRA® (adalimumab) Approved in Europe for Treatment of Ulcerative Colitis (UC)
http://www.pharmanews.eu/abbott/1034-abbotts-humirar-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc
http://www.pharmanews.eu/abbott/1034-abbotts-humirar-adalimumab-approved-in-europe-for-treatment-of-ulcerative-colitis-uc
With best regards,
Ruslan David
Administrator/Editor
Ruslan David
Administrator/Editor
PS: Want to place your News, Brand, Service, Product or Event in front of World Pharma News?
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
World Pharma News' strong, innovative capabilities can ensure you to create a compelling advertising campaign that reaches all your objectives and desired audiences. For further information, please download World Pharma News' Media Pack (.pdf, 319 KB).
http://www.worldpharmanews.com/contact-us
Reply all
Reply to author
Forward
0 new messages